Prognostic Models for Predicting the Severity and Mortality in People With Acute Pancreatitis - A Systematic Review and Meta-Analysis.

J Surg ResSep 30, 2026 (epub)
Clinical ResearchGastroenterology

Angus Hann, Anne Nagelhout, Gianluca Rompianesi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed how accurately four clinical scoring systems predict severe acute pancreatitis (SAP) and mortality in adults. It included 87 studies, comprising 92 cohorts and 65,942 participants. The highest pooled AUCs for predicting SAP ranged from 0.82 to 0.88 across the scores; for mortality, they ranged from 0.86 to 0.89. The authors found no evidence that any one system outperformed the others, and reported that accuracy varied with the timing of assessment.

Key findings

  • For SAP, the highest pooled AUC was 0.88 (0.83-0.92) for Glasgow-Imrie within 48 h.
  • For mortality, the highest pooled AUC was 0.89 (0.84-0.92) for BISAP within 24 h.
  • The review found no evidence that Ranson, Glasgow-Imrie, APACHE II, or BISAP was superior for predicting SAP or mortality.
  • Predictive accuracy varied according to when the scoring system was performed.

Why it matters

These findings help frame the role of commonly used scores in early risk assessment: each showed predictive accuracy, but the pooled results do not establish one as best. Because performance varied with assessment timing, interpreting a score requires attention to when it was calculated as well as which system was used.

What to keep in mind

The review included studies with differing assessment times and pooled results across multiple cohorts; the abstract does not report comparative evidence establishing superiority between scores.

Source

Published in J Surg Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.